Sign in Subscribe
Pharmaceutical industry

Multiple Myeloma Pipeline Landscape: Insights into Novel Therapies and Key Players

Strategic Insights

— 1 min read

The multiple myeloma pipeline landscape is rapidly evolving, with numerous companies and research institutions working towards the development of innovative treatment therapies. A report by DelveInsight highlights the presence of over 80 companies and 120 pipeline drugs, indicating a significant surge in research and development efforts. Key players such as Cartesian Therapeutics, AbbVie, and Roche, Janssen, Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., and Regeneron Pharmaceuticals are driving the development of novel treatments for multiple myeloma.

Key Takeaways:

  • Over 80 companies and 120 pipeline drugs are currently being developed for the treatment of multiple myeloma.
  • Companies such as Cartesian Therapeutics, AbbVie, and Roche, Janssen, Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., and Regeneron Pharmaceuticals are at the forefront of multiple myeloma research and development.
  • Emerging therapies such as Descartes-11, Venetoclax, Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M), and Keytruda (Pembrolizumab) are expected to have a significant impact on the multiple myeloma market in the coming years.
  • The pipeline landscape is characterized by a strong focus on immunotherapy, with several companies exploring the potential of checkpoint inhibitors and CAR-T cell therapies.
  • DelveInsight's report provides in-depth insights into the multiple myeloma pipeline, including clinical and non-clinical stage products, and highlights the most promising pipeline therapies.
  • The report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, providing a comprehensive understanding of the multiple myeloma therapeutics landscape.

Statistics:

  • Over 80 companies are engaged in the development of multiple myeloma therapies.
  • 120 pipeline drugs are currently being developed for the treatment of multiple myeloma.
  • The pipeline landscape is characterized by a strong focus on immunotherapy, with 60% of pipeline therapies employing immunotherapy mechanisms.
  • The most promising pipeline therapies include Descartes-11, Venetoclax, Ciltacabtagene Autoleucel (cilta-cel/ JNJ-68284528/LCAR-B38M), and Keytruda (Pembrolizumab).
  • The multiple myeloma market is expected to witness significant growth in the coming years, driven by the increasing awareness of the disease and the development of novel therapies.

Sources:

  • DelveInsight's "Multiple Myeloma (MM) - Pipeline Insights, 2021" report.
  • DelveInsight's "Multiple Myeloma (MM) - Market Insights, Epidemiology, and Market Forecast-2030" report.
  • DelveInsight's Multiple Myeloma - Epidemiology Forecast to 2030 report.
  • M2 PressWIRE, September 20, 2021.

Read more